0.65
+0.0246(+3.92%)
Currency In USD
Address
2500 Westchester Avenue
Purchase, NY 10577
United States of America
Phone
412 481 2210
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
October 08, 2021
| Name | Title | Pay | Year Born |
| Ms. Lisa Ricciardi | Chief Executive Officer, President & Director | 854,148 | 1960 |
| Mr. John Brendan Doyle | Chief Financial Officer | 414,884 | 1977 |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | 616,275 | 1970 |
| Dr. Steven A. Weissman Ph.D. | Vice President & Head of CMC | 0 | N/A |
| Ms. Anita Cornet | Head of Quality | 0 | N/A |
| Mr. Bobby Horn | Corporate Controller | 0 | N/A |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.